The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
up to 18 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age≤18 years old, gender no limited.
Patients with acute lymphoblastic leukemia diagnosed by bone marrow pathology or cytology.
Plan to receive CAM (cyclophosphamide,cytarabine,6-MP)chemotherapy regimen.
Previously not received radiotherapy.
Karnofsky Performance Scores ( KPS)≥60.
The expected survival time was ＞3 months.
Neutropenia or agranulocytosis, no bleeding tendency.
No significant cardiac dysfunction or metabolic disease.